Glenmark Pharmaceuticals Ltd Q2 FY2026 Concall Summary

Key Takeaways

• India revenue collapsed 87% YoY on a one-time GST-driven distributor inventory correction, but secondary sales grew 10.8% and management expects a full recovery to a ₹1,150–1,200 crore quarterly run rate from Q3.
• ISB 2001 deal closed and cash deployed: the \$700 mn upfront was used to repay ₹1,300 crore gross debt, fund ₹650 crore in one-time charges, and absorb a ₹1,600 crore working capital swing, leaving ₹2,647 crore in closing cash.
• Balance sheet restated, legacy arrangements unwound: high-cost pre-collection arrangements were discontinued and provisioning norms revised, inflating debtors by ~₹800 crore but setting the stage for improved operating margins and return ratios going forward.
• IGI pipeline positioned as a multi-year value driver: management claims each of the 4+ multi-specific programs entering clinics over the next 5 years could be as valuable as ISB 2001, and the unit is self-funded for 3 years.
• What to watch next quarter: whether India reported sales actually rebound to the promised ₹1,150–1,200 crore, the pace of U.S. ANDA launches, and any further one-time charges or balance sheet adjustments despite management calling them done.

India Business: The GST Shock and Recovery

• The 87% drop was mechanical, not demand-driven: the August 15 GST regime change announcement triggered distributors to slash inventories because of rate differentials, and Glenmark's unique 3-tier super-stockist distribution model amplified the impact relative to peers on C&F models. Freight and reverse logistics costs added to the disruption, alongside a base effect from discontinued tail-end products.
• Secondary sales tell the real story: IQVIA secondary sales grew 10.8% in Q2 and 11.4% on a MAT September basis, outperforming the market and confirming underlying demand is intact.
• The recovery promise is specific: management expects India reported sales to return to ₹1,150–1,200 crore from Q3 onwards, and to deliver over ₹4,800 crore in FY27 top line, with reported growth aligning with secondary sales growth starting Q3.
• This is not a repeat of the Q3 FY24 restructuring: that earlier event consolidated stock points to address distribution inefficiencies; the current correction is purely GST-driven and management says distributor inventories have now fallen below threshold levels, with restocking expected.

Glenn Saldanha: "This is the best phase of Glenmark I have ever seen in the last 25 years as we are making an orbital change for Glenmark, which allows us to reflect the true potential of the company."

ISB 2001: Deal Closed, Cash Deployed, Pipeline Implications

• The deal mechanics: Glenmark received U.S. FTC approval and the \$700 mn upfront payment in September, with eligibility for up to \$1.225 bn in milestones plus double-digit royalties, while retaining commercialization rights in emerging markets.
• Cash reconciliation from the upfront: of the ~₹5,950 crore received, ₹1,300 crore went to gross debt repayment, ₹75 crore to cash tax, ₹150 crore to interest, ₹500 crore to H1 capex, ₹650 crore to one-time expenses (IGI bonuses, deal costs, Switzerland facility closure, legal settlement), and ₹500 crore covered the H1 business cash deficit. A ₹1,600 crore working capital swing (₹800 crore debtors from pre-collection discontinuation plus inventory build) left closing cash at ~₹2,647 crore.
• The one-time charge basket is broad: the ₹650 crore includes employee bonuses (including R&D team incentives benchmarked to biotech peers), legal charges, due diligence and consultant fees across Europe and the U.S., LCDF closure charges, employee-related liability settlements, local regulatory liabilities, and IP/documentation transfer charges for ISB 2001. Management declined to break out specific line items citing confidentiality.
• IGI cash flow structure: the entire \$700 mn came under Glenmark non-IGI entity control physically via loan, dividend or other flow-through; IGI will receive \$70 mn per annum for 3 years as capital allocation, with a matching revenue and expense line in the P&L that neutralizes.
• The strategic shift in deal-making: management contrasted past deals with \$20–50 mn upfronts driven by cash constraints against the ISB 2001 outcome, arguing the strong balance sheet now lets Glenmark realize full pipeline potential.

Balance Sheet Reset: Pre-Collection, Provisioning, and Return Ratios

• Pre-collection arrangements discontinued: legacy high-cost arrangements with distributors across geographies, costing up to 20% in some cases, were stopped, causing a large increase in debtors (~₹800 crore) but supporting improved operating margins going forward.
• Provisioning norms revised: policies on debtors and inventory were restated to better reflect true return ratios; management described the resulting charges as cash-neutral and tax-efficient, and discussed them thoroughly with the new auditor.
• Management calls this the end of legacy clean-up: when asked directly whether more corrections are coming, management said they are "pretty much done" and there are "no further changes in either the P&L or balance sheet corrections which need to get done going forward."
• Return ratio ambition is aggressive: management targets industry-best ROCE of ~25–30% and ROE of 20–25% in FY27 and beyond, with net working capital sustained at ~110–115 days.
• Historical context for the clean-up: the last 4–5 years were marked by Monroe issues, FDA challenges that idled a facility for 3–4 years, intangibles write-downs, and Zetia class action lawsuits, all described as impossible to predict operationally.

Glenn Saldanha: "In the early years, some of our previous deals were in the range of \$20 million to \$50 million upfront because we needed the cash. Now that we have a strong balance sheet and are well funded, we are in a position to realize the full potential of the pipeline similar to what we did with ISB 2001."

IGI Pipeline: Multi-Specific Platform as the Next Value Driver

• The platform claim is bold: management asserts that not many companies, including oncology-focused big pharma, have a multi-specific antibody platform technology, calling it a unique competitive advantage. All programs are more than trispecific, with multiple binding sites on the antibody.
• ISB 2301 is the nearest catalyst: a clinical candidate was selected in October and has entered IND-enabling studies; it is a first-in-class multi-specific NK cell engager for solid tumors from the IMMUNITE platform, expected to enter clinics in FY27.
• The pipeline depth: over 4 multi-specific preclinical and discovery programs are expected to enter clinics over the next 5 years, with management claiming each could be as valuable as ISB 2001 and produce large out-licensing deals.
• IGI is self-funded for 3 years: post that period, management expects additional milestones from partnered assets, potential new deals for the 4 programs, and possibly an IPO.
• Other pipeline updates: ISB 880 (LAD191, licensed to Almirall) moved into Phase II for Hidradenitis Suppurativa; ISB 830-X8 (STAR-310, OX40 antagonist licensed to Astria) entered Phase I with positive initial efficacy and safety data presented at a European dermatology conference, showing potential for infrequent maintenance dosing.

Glenn Saldanha: "Not too many companies, including oncology-focused big pharmas have a multi-specific antibody platform technology. So this is very unique and gives us a huge competitive advantage."

Geographic Performance Outside India

• North America headline inflated by licensing income: reported sales of ₹4,465.6 crore included ISB 2001 out-licensing income; the core business grew 7.4%, supported by two injectable launches (Micafungin, Eribulin Mesylate).
• Europe returned to growth at 8.5%: driven by robust uptake of new product launches, with branded markets in Central and Eastern Europe outperforming the overall pharma market, Western Europe recording double-digit growth, and the branded respiratory portfolio performing strongly. WINLEVI launched in the U.K. with very positive initial response, and partner Cosmo received a positive CHMP opinion in August 2025.
• Emerging markets declined 6.5%: geopolitical uncertainties lowered uptake in Latin America and Middle East Africa, while Russia did well with 8.1% secondary growth and APAC recorded double-digit growth.
• U.S. FY27 set-up: management expects 3 sole FTF/exclusive product launches in FY27, plans to file 2 ANDAs in the upcoming quarter, and aims to launch 3–4 products each quarter going forward. Two generic nasal spray ANDAs are awaiting approval, and an ANDA for generic Flovent 44mcg has been filed.
• Partnered product launches progressing: TEVIMBRA and BRUKINSA launched in India with strong uptake; JABRYUS (with Pfizer) launched for atopic dermatitis; RYALTRIS approved in China with launch expected in H1 of the coming fiscal year, and in Thailand via Organon in Q4 of this year; QIN HAYO (Envafolimab) has 14 applications filed with first commercial launch expected towards end of this year.

Guidance & Commitments

Key Metrics